Percutaneously implanted markers in peripheral lung tumours: Report of complications

Figures & data

Figure 1. Photo showing the complex helical platinum marker (top), the Gold Anchor^TM marker (middle) and the Visicoil^TM gold marker (bottom).

Table I. Patient characteristics.

Age*		73 (60–87) years
Gender	Female/Male	7/8
FEV1*		1.4 (0.7–3.4) l
Diagnosis	NSCLC:
	Primary	11
	Recurrent	3
	Lung metastasis	1
Prior lung resection	Wedge resection	2
	Lobectomy	1
Tumour location	Upper lobe	6
	Lower lobe	9
Tumour size*	Volume	13.6 (1.7–46.3) cm^3
Tumour motion*	Left-Right	0.2 (0.1–0.3) cm
	Antero-Posterior	0.2 (0.1–0.4) cm
	Cranio-Caudal	0.6 (0.1–2.4) cm

*Median (range).

Figure 2. Chest x-rays showing different marker types. Patient 1 had a 2 cm long helical gold marker (Visicoil^TM) implanted in the tumour in the right inferior lung lobe (left). Patient 6 had the complex helical platinum marker (Boston Scientific) implanted in the tumour in right superior lung lobe (middle). Note that the marker was placed outside the tumour. The patient had a pacemaker. Patient 11 had the Gold Anchor^TM marker implanted in the tumour in the right inferior lobe (right). The arrows indicate the position of the markers.